v3.26.1
Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Product Information [Line Items]          
Research and development expense $ 114,621 $ 112,364 $ 235,530 $ 236,397  
Conversion of preferred shares 8,044,884       8,044,884
Operating loss carryforwards $ 3,969,427   $ 3,969,427    
Net operating losses carryforwards, expire date     begin to expire in 2027    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]          
Product Information [Line Items]          
Concentration risk percentage     10.10%   16.70%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]          
Product Information [Line Items]          
Concentration risk percentage     10.50%   10.20%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]          
Product Information [Line Items]          
Concentration risk percentage     13.40%